22-09-2025, 22:02

Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset

Notified -
Globe Newswire22-09-2025, 22:02
21-10-2024, 11:00

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
Globe Newswire21-10-2024, 11:00